Acceleron Pharma Inc. (XLRN) Has Broken Out To A New High On Study Results
Markets2018-06-29
14 Views
Acceleron Pharma Inc. (XLRN) and Celgene (CELG) announced after the bell Thursday that the Phase 3 study of Luspatercept met its primary and key secondary endpoints.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
BioNTech (Nasdaq: BNTX) and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
